OT: Zacks upped ONCS PT by $2 from $2 to $4 this week on the heels of Merck letting ONCS use their FDA drug for trials. At .62, ONCS may be a great opportunity. 4 milestones left to be announced by year end as I understand it.
It sure did. Look around 11:19. Now quit spreading misinformation around here. Nobody gives you too much credit around here as it is. Really,..Who would want to short ONCS at these levels with catalysts lined up?
I have reshuffled the deck in my portfolio and out some $ to work at ONCS. 4 milestones (catalysts) to be announced in the next 30 days, Zacks just bumped their PT to $4 this week, and partnership with Merck announced this week and Plexxikon last week speaks volumes for a .60 stock. Good info on ihub ONCS.
I just added again today to my position today in ONCS. Looks like they have several milestones to announce yet by year end for catalysts. They were also mentioned on Financial Buzz after the partnership they announced involving Merck that was announced this week,...
Volume was really good imo for the shortened day after Turkey Day trading session. This has been a very productive week for ONCS setting us up well (200 day ma) to launch on more positive news.
I think any run up here can safely be sold until positive news is announced in Q1 sometime. Unfortunately,....
ONCS looks good to me with catalysts lining up for December starting next week. 4 milestone announcements to come this year yet, Zacks just bumped their price target up for ONCS last week by $2, and Partership with Merck letting them use their FDA approved drug announced this week is big. Google Financial Buzz ONCS,..more good press.
I will be revisiting RXII sometime in Q1 and take another serious look.
Volume precedes price typically. Something or somebody is accumulating big time here this week. Being that conferences are coming up,...$3.17, $3.50, $4.00, $4.50, $4.80, $5??
Sentiment: Strong Buy